Xience, Promus from Boston Scientific- New Drug Stents

From Abbot Medical: Once again, Abbott is leading the wave of innovation in stent technology. The XIENCE V Drug Eluting Stent's proven design combines the deliverability of MULTI-LINK VISION with a biocompatible fluorinated copolymer and everolimus to assist in increased treatment success for patients with coronary artery disease (CAD).

Abbott announced that FDA approved the XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.

The Xience represents the fourth Drug Eluting Stent approved following the Cypher and Taxus from J&J and Boston Scientific respectively. Earlier this year the Endeavor was released from Medtronic. Interestingly, as a consequence of the original Guidant buyout deal, two identical stents will be released. The Promus from Boston Scientific and the Xience from Abbott

See Video of the stent